Skip to main content

Evercore ISI Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Tipranks - Tipranks - Wed Feb 25, 7:49AM CST

In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $110.00.

Claim 50% Off TipRanks Premium

Kasimov covers the Healthcare sector, focusing on stocks such as Zenas BioPharma, Inc., Neurocrine, and Vertex Pharmaceuticals. According to TipRanks, Kasimov has an average return of 15.8% and a 56.82% success rate on recommended stocks.

In addition to Evercore ISI, BioMarin Pharmaceutical also received a Buy from TD Cowen’s Phil Nadeau in a report issued today. However, on the same day, William Blair maintained a Hold rating on BioMarin Pharmaceutical (NASDAQ: BMRN).

See the top stocks recommended by analysts >>

Based on BioMarin Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $776.13 million and a GAAP net loss of $30.74 million. In comparison, last year the company earned a revenue of $745.74 million and had a net profit of $106.08 million

Read More on BMRN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).